Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 11, 2008, Pages 1265-1269

  Terpos, Evangelos ^a   Christoulas, Dimitrios ^a   Dimopoulos, Meletios Athanassios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

B ligand (RANKL); Bone formation; Bone metastasis; Multiple myeloma; Osteoporosis; Receptor activator of nuclear factor ; Rheumatoid arthritis

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14F3; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR MONOCLONAL ANTIBODY FC; PROTEIN ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG;

BIOLOGICAL ACTIVITY; BONE DISEASE; BONE METASTASIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATENT; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

EID: 56849106456     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.11.1265     Document Type: Review

References (36)

1. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390(6656):175-9
2. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999;96(7):3540-5
3. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186(12):2075-80
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-76
5. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602
6. Darnay BG, Besse A, Poblenz AT, et al. TRAFs in RANK signaling. Adv Exp Med Biol 2007;597:152-9
7. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappa-B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29(2):155-92
8. Bai S, Zha J, Zhao H, et al. TRAF6 is an intranuclear transcriptional co-activator in osteoclasts. J Biol Chem 2008;In press
9. Tomoyasu A, Goto M, Fujise N, et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 1998;245(2):382-7
10. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19
11. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473(2):139-46
12. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-23
13. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13(18):2412-24
14. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000;97(4):1566-71
15. Väänänen HK, Laitala-Leinonen T. Osteoclast lineage and function. Arch Biochem Biophys 2008;473(2):132-8
16. Josien R, Wong BR, Li HL, et al. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999;162(5):2562-8
17. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402(6759):304-9
18. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008;29(4):403-40
19. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9(4):1436-40
20. Standal T, Seidel C, Hjertner O. et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002-7
21. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98(13):3527-33
22. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003;102(3):1064-9
23. Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007;46(2):221-9
24. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25(2):119-29
25. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008;68(1):92-104
26. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-27
27. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008;358(22):2355-65
28. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29(6):498-505
29. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol 2005;74(4):359-61
30. Oelzner P, Franke S, Lehmann G, et al. Soluble receptor activator of NF-kappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 2007;26(12):2127-35
31. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008;57(5):684-94
32. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21(9):1875-84
33. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110(4):1098-104
34. Whyte MP. Paget's disease of bone and genetic disorders of RANKL/OPG/ RANK/NF-kappaB signaling. Ann NY Acad Sci 2006;1068:143-64
35. Mcclung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31
36. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25(28):4431-7